| Revision as of 23:22, 10 February 2013 editStar767 (talk | contribs)3,516 editsm Star767 moved page Richard Barker (Dr) to Richard Barker (healthcare expert): Incorrect to use (Dr) as part of name← Previous edit | Revision as of 23:39, 10 February 2013 edit undoStar767 (talk | contribs)3,516 edits publicationNext edit → | ||
| Line 16: | Line 16: | ||
| He chairs the South London Academic Health Science Network, which aims to improve the quality and consistency of care in that part of the ], and to facilitate innovations emerging from academic and industrial research into NHS application. | He chairs the South London Academic Health Science Network, which aims to improve the quality and consistency of care in that part of the ], and to facilitate innovations emerging from academic and industrial research into NHS application. | ||
| ==Recent publications== | |||
| ==Publications== | |||
| 2030 - the Future of Medicine <ref>http://2030healthfutures.com/</ref> | *2030 - the Future of Medicine <ref>http://2030healthfutures.com/</ref> | ||
| *"Adaptive drug development and licensing", Richard Barker & Sarah Garner, in ''Regulatory Rapporteur'', Vol 9, No 10, October 2012.<ref>http://www.aptivsolutions.com/wp-content/uploads/2012/09/Regulatory-Rapporteur-October-2012.pdf, Regulatory Rapporteur, coauthored with Sarah Garner</ref> | |||
| ==Personal Life== | ==Personal Life== | ||
Revision as of 23:39, 10 February 2013
| This article may meet Misplaced Pages's criteria for speedy deletion as an article about a real person that does not credibly indicate the importance or significance of the subject. Note that this criterion applies only to articles about people themselves, not about their books, albums, shows, software, etc. See CSD A7.%5B%5BWP%3ACSD%23A7%7CA7%5D%5D%3A+Article+about+a+real+person%2C+which+does+not+%5B%5BWP%3ACCS%7Ccredibly+indicate+the+importance+or+significance%5D%5D+of+the+subjectA7
If this article does not meet the criteria for speedy deletion, or you intend to fix it, please remove this notice, but do not remove this notice from pages that you have created yourself. If you created this page and you disagree with the given reason for deletion, you can click the button below and leave a message explaining why you believe it should not be deleted. You can also visit the talk page to check if you have received a response to your message. Note that this article may be deleted at any time if it unquestionably meets the speedy deletion criteria, or if an explanation posted to the talk page is found to be insufficient.
Note to administrators: this article has content on its talk page which should be checked before deletion. Administrators: check links, talk, history (last), and logs before deletion. Please confirm before deletion that the page doesn't seem to be intended as the author's userpage. If it does, move it to the proper location instead. Consider checking Google.This page was last edited by Star767 (contribs | logs) at 23:39, 10 February 2013 (UTC) (11 years ago) |
Richard Barker is currently Director of the Centre for the Advancement of Sustainable Medical Innovation (CASMI). He has devoted much of his career to improving the process of bringing medical innovations to patients, both in the course of a long business career and as a contributor to academic research and public policy.
Education
He was educated at Alleyn's School, London and Exeter College Oxford, where he received a BA in Chemistry. He went on to focus his research on biological applications of magnetic resonance techniques, in an Oxford DPhil and in post-doctoral periods in Munich and Leeds.
Career
His business career has spanned both Europe and the US. After a period with McKinsey, in which he headed the European Healthcare practice and also advised UK, Swiss and US pharmaceutical companies, he held a succession of senior appointments in the US. As General Manager of IBM's healthcare business, he launched Healthvillage, one of the earliest Internet healthcare applications. At Chiron, he headed the diagnostics business, which brought the latest immunodiagnostics to market. He subsequently served as chairman and chief executive of Molecular Staging, whose genome amplification technology enables gene sequencing on rare DNA samples.
On returning to the UK, he headed the Association of the British Pharmaceutical Industry (ABPI) and initiated policy programmes in areas such as stratified medicine, and launched frameworks for translational partnerships between academia and industry. He formed and chairs Stem Cells of Safer Medicines, a public/private partnership formed to develop new approaches to testing potential new medicines for toxicity.
With colleagues in Oxford and UCL, he has formed CASMI to develop, test and promote new models of medical innovation. These include adaptive licensing, cell therapy regulation and a combination of therapeutic and diagnostic products to focus treatments on the patients most likely to benefit.
He chairs the South London Academic Health Science Network, which aims to improve the quality and consistency of care in that part of the NHS, and to facilitate innovations emerging from academic and industrial research into NHS application.
Recent publications
- 2030 - the Future of Medicine
- "Adaptive drug development and licensing", Richard Barker & Sarah Garner, in Regulatory Rapporteur, Vol 9, No 10, October 2012.
Personal Life
Richard lives in London, is married to Michaela Barker and has three children and a number of grandchildren. He enjoys mountain walking and music.
- "Dr Richard W. Barker". innovativiondebate.com. Retrieved 10 February 2013.
- http://2030healthfutures.com/
- http://www.aptivsolutions.com/wp-content/uploads/2012/09/Regulatory-Rapporteur-October-2012.pdf, Regulatory Rapporteur, coauthored with Sarah Garner